60
Participants
Start Date
September 1, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
Blinatumomab
"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 (8 to 21 days in total), followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhenzhou
Suping ZHANG
OTHER